Navigation Links
Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment
Date:12/6/2013

ts that had initiated TI in the SB-728-902 Cohort 5 study and an additional CCR5 delta-32 heterozygote subject from an earlier Phase 1 clinical trial of SB-728-T. One SB-728-902 Cohort 5 subject, who had the highest levels of estimated biallelically modified cells and measurable immunological responses to the virus (polyfunctional anti-gag response), demonstrated sustained control of VL at or below the limits of detection, which is ongoing for more than 20 weeks into the TI.

The SB-728-1101 study aimed to demonstrate enhanced engraftment of SB-728-T modified CD4 cells following cyclophosphamide (Cytoxan) preconditioning. Cytoxan is a drug that is used to transiently reduce the numbers of T-cells in the body, which then rapidly repopulate once the drug is discontinued and it is into this "growth" environment that SB-728-T is infused. This study was successful in showing a Cytoxan-dose dependent increase in both SB-728-T and total CD4 T-cells at the beginning of the treatment interruption, which in the top dose tested (1g/m2) approached the engraftment levels observed in CCR5 delta 32 heterozygote VL responders, and resulted in up to a two-log decrease in VL in one of three subjects who remains on TI and a 0.8-log decrease in a second subject. In the study, a total of twelve subjects were treated in three cohorts of escalating doses of Cytoxan (three subjects at 200 mg, six subjects at 500 mg/m2and three subjects at 1000 mg/m2). All doses tested were safe and well-tolerated although two of the first three subjects in the second cohort experienced Grade 2 nausea, which was reversed using an improved anti-emetic regimen that  was further tested with an additional three subjects (total of six subjects at this dose level). Cytoxan dose-dependent increases were observed in both SB-728-T and total CD4 T-cells. The study has been expanded to test an additional six subjects in two cohorts of three at Cytoxan doses of 2.0 and 3.0 g/
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
2. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
4. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
5. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
7. Sangamo BioSciences Reports First Quarter 2013 Financial Results
8. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
9. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
10. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
11. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
(Date:1/23/2015)... Companies, Inc. (ICBU) has repositioned itself as a holding company ... foothold in the hydroponic, hemp and medical marijuana sectors. By ... the sector, and recently partnering with the Chippewa Tribe Nation ... marijuana, iMD is committing to bring its vision to the ...
(Date:1/23/2015)... Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Proxy Statement, Schedule 14A, with the U.S. Securities & Exchange ... shareholders detailing why a "YES" vote to increase the number ... As we reflect upon the 2014 fiscal year that ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... 2011 /PRNewswire-Asia/ -- Pharmaceutical company Hatchtech Pty Ltd has ... study to confirm the efficacy of its novel head ... is evaluating the efficacy, safety and tolerability of two ... to vehicle. The trial consists of treating 132 healthy ...
... Aug. 31, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... appointed Helen Torley, M.B. Ch. B., M.R.C.P.,  as Executive ... Dr. Torley will report to N. Anthony Coles, M.D., ... for all commercial activities related to Nexavar and the ...
Cached Medicine Technology:Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 2Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 3Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 2Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 3
(Date:1/22/2015)... January 22, 2015 Woodloch Pines, an ... been selected by TripAdvisor as the number one best large ... best in the world for their annual Travelers’ Choice Awards. ... community . The website is home to millions of unbiased ...
(Date:1/22/2015)... 23, 2015 VogueQueen is a seasoned and ... and many designers are thrilled to have it lead the ... its new collection of prom dresses for the global market. ... the strategic vision and he focuses on continuing the goal ...
(Date:1/22/2015)... EAGAN, Minn. (PRWEB) January 22, 2015 Blue ... discover those Minnesotans who exemplify what it means to “Live ... a chance for people to share their stories about how ... adversity or simply inspired others by living in the moment. ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... full, study suggests , , MONDAY, June 16 (HealthDay News) -- ... sweeteners may help you feel fuller faster and decrease the ... this may be a new way to help people lose ... can stimulate the sense of taste -- included 2,436 overweight ...
... La.The first patient scans from a custom-built scanner ... (CT) technologies indicate that these scans could significantly ... more targeted treatment options, according to researchers at ... designed to help physicians determine stages of breast ...
... NEW ORLEANS, La.A new study, presented at the ... pre-target the treatment of cancer cellsbringing personalized medicine ... By combining new molecular imaging techniques with targeted ... treatment that can increase the effectiveness of therapies ...
... tomography (PET) and computed tomography (CT) scanning of ... can enable physicians to determine whether the cancer ... to perform surgery, according to researchers at the ... surgeries could be reduced, which would also lower ...
... are developing new technology to create individualised brain maps ... accuracy of brain surgery. , Currently researchers and ... that are based on a small number of individuals, ... differences that can occur between people,s brains. , The ...
... Jersey Hospital, RIDGEWOOD, N.J., June 16 Ridgewood resident,David ... historic charitable contribution to The Valley Hospital in,Ridgewood, NJ. The ... its main campus, is thought to be the largest single ... gift to Valley because I want my giving to do ...
Cached Medicine News:Health News:Flavoring Food May Promote Weight Loss 2Health News:Flavoring Food May Promote Weight Loss 3Health News:New possibilities for breast cancer treatment on the horizon 2Health News:Personalizing medicine: New research shows potential of targeted therapies for cancer 2Health News:PET/CT scan could be valuable noninvasive tool for determining stages of ovarian cancer 2Health News:Developing unique brain maps to assist surgery and research 2Health News:The Valley Hospital in Ridgewood, NJ, Announces Historic $30 Million Gift 2
... is a major upgrade of ... important physical and software changes ... and increase efficiency. The ACS:180 ... ACS:180. The productivity of the ...
... of Platelet aggregometers allows to choose ... needs. Single, dual and four sample ... outputs or digital computer outputs. In ... which measure platelet aggregation in platelet-rich-plasma ...
... four channel Platelet Aggregation Profiler with three ... (Ristocetin cofactor), platelet aggregation and leukocyte aggregation. ... the evaluation and confirmation of Heparin Induced ... to be run simultaneously and independently. Select ...
... a four channel platelet aggregation profiler with ... von Willebrand assay (Ristocetin cofactor), platelet aggregation ... be used for the evaluation and confirmation ... allow four tests to be run simultaneously ...
Medicine Products: